TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06549309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JMKX003801
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohort of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohorts of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.
Study: NCT05123053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine
Description: 10mg tablet
Study: NCT06292507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MYOFASCIAL STRETCH
Description: Group A 10 participants will receive Myofascial Stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTRACT-RELAX TECHNIQUE
Description: group B 10 participants will receive Control-Relax Stretching Technique.
Study: NCT05733377

Intervention type: DIAGNOSTIC_TEST
Intervention: Arrow Test
Description: It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.

Intervention type: DIAGNOSTIC_TEST
Intervention: Angle measurement by imaging device
Description: First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
Study: NCT05529602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: core stability exercises~A total of 3 sessions per week were given for 15-20 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: relaxation exercise
Description: the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes
Study: NCT05663554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Intervention
Description: The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
Study: NCT04883047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: holistic birth support strategies
Description: Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy.
Study: NCT04706325

Intervention type: OTHER
Intervention: ACUTE KIDNEY INJURY
Description: KDIGO LEVELS
Study: NCT05867121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7496353
Description: RO7496353 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7496353
Description: RO7496353 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7496353
Description: RO7496353 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Study: NCT04706325

Intervention type: OTHER
Intervention: ACUTE KIDNEY INJURY
Description: KDIGO LEVELS

Intervention type: OTHER
Intervention: ACUTE KIDNEY INJURY
Description: KDIGO LEVELS
Study: NCT05867121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered as per the schedules specified in the respective arms
Study: NCT06498180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal initial treatment under local anesthesia
Description: Removal of plaque retention factors, supragingival scaling and subgingival scraping under local anesthesia with articaine (combined with manual and ultrasound methods), and polishing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid Therapy
Description: Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
Study: NCT06498180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid Therapy
Description: Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
Study: NCT04962646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide flooding
Description: Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
Study: NCT06421207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ellacor® Micro-Coring procedure
Description: ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ellacor® Micro-Coring procedure
Description: ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Study: NCT05806723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: daily drug intake during six months
Study: NCT05093348

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Click2Print artificial eye
Description: Digitally designed and manufactured ocular prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-made artificial eye
Description: Hand-made artificial eye
Study: NCT05074043

Intervention type: COMBINATION_PRODUCT
Intervention: antiviral, surgical
Description: surgical debridment
Study: NCT06356090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions (SPACE)
Description: SPACE is a parent-based treatment (parent-stand-alone treatment) for parents of youth with anxiety symptoms or OCD. The manualized treatment protocol contains 12 sessions, in which parents are taught to reduce family accommodation (FA) and to increase supportive responses to their child.
Study: NCT04579029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging
Description: Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
Study: NCT05867121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as per the schedules specified in the respective arms.
Study: NCT06333821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40mg/m\^2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: External Beam Radiotherapy (EBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: External Beam Radiotherapy (EBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy
Study: NCT05867121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the schedules specified in the respective arms.
Study: NCT06188559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
Study: NCT06333821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for Nimotuzumab
Description: placebo for Nimotuzumab 400mg
Study: NCT06533254

Intervention type: OTHER
Intervention: Predicting choice of dialysis
Description: Language data collected using survey 1, will be analyzed using Scaled Insights Behavioral AI solution to identify personality attributes and values. The resulting individual scores will be plotted on a graph and be used to identify specific personality clusters of patients.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.~The open-ended questions will gather a natural language sample of 100-300 words for analysis using Scaled Insights Behavioral AI approach. This language sample will be analyzed using Scaled Insights Behavioral AI system to identify personality attributes and values. Patients will also be asked their likelihood of selecting PD over HD.

Intervention type: BEHAVIORAL
Intervention: Behavioral nudges
Description: Patients with Chronic Kidney Disease, participants will be provided with their predicted personalized nudge to increase their likelihood of either maintaining their choice of peritoneal dialysis, or switching from hemodialysis to peritoneal dialysis.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.
Study: NCT06498453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trak-Physio knee condition
Description: The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trak-Physio in shoulder condition
Description: The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee conventional rehabilitation program
Description: Exercise protocol with the methodology of conventional clinical practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder conventional rehabilitation program
Description: Exercise protocol with the methodology of conventional clinical practice.
Study: NCT06150885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-G-CAR.BiTE allogeneic γδ T cells
Description: Phase I is a multiple escalating dose, single arm, open-label and 3+3 design that implemented with five cohorts: low dose for single administration, low dose for twice administrations for 2 weeks, low, middle and high dose for 4 repeated administrations for 4 weeks.~Phase IIa is a single-arm, open-label and dose-expansion study and the effective dose of CAR-positive cells will be administered to 27 evaluable subjects with TNBC, NSCLC, CRC or GBM via intravenous infusion weekly for 4 weeks.
Study: NCT05435885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Tele-Rehabilitation
Description: 12 supervised training sessions via a specific mobile messenger during four weeks. (3 sessions/week)

Intervention type: OTHER
Group type: OTHER
Intervention: Control (Education)
Description: Usual care with only one educational session.
Study: NCT05133167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Tamponade or B-Lynch
Description: In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Tamponade or B-Lynch
Description: In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.
Study: NCT04833140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol patch
Description: The patch will provide 100mcg of estradiol daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch will contain no estradiol.
Study: NCT05890911

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Each of the patients will undergo polysomnography

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Each of the patients will undergo polysomnography

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood dopamine level measurement
Description: In each of the patients blood dopamine level will be measured

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood dopamine level measurement
Description: In each of the patients blood dopamine level will be measured

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetical test
Description: Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetical test
Description: Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).
Study: NCT05577962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T group
Description: OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
Study: NCT06107413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion
Study: NCT06498180

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: oral hygiene instruction
Description: Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral hygiene instruction
Description: Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes
Study: NCT05087446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early assessment team
Description: Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Admission to General psychiatric outpatient clinic
Description: Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
Study: NCT06181058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: escape room game
Description: Participants will be informed about the game (15 minutes). They will complete the game by solving puzzles within the framework of the oncology patient scenario (approximately 30 minutes). There will be a debriefing session at the end of the escape game (15 minutes).
Study: NCT05722769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CSTOP Now!
Description: Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevent Child Abuse Kentucky Online Training
Description: The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.